Mesa Laboratories (NASDAQ:MLAB) Research Coverage Started at Wells Fargo & Company

Wells Fargo & Company assumed coverage on shares of Mesa Laboratories (NASDAQ:MLAB) in a research report issued on Tuesday, Benzinga reports. The firm set an “underweight” rating and a $120.00 price target on the medical instruments supplier’s stock. Wells Fargo & Company‘s price objective suggests a potential downside of 14.81% from the stock’s previous close.

Separately, Evercore ISI upped their price target on Mesa Laboratories from $106.00 to $120.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 6th.

Mesa Laboratories Stock Up 2.3 %

Shares of MLAB traded up $3.11 on Tuesday, hitting $140.86. The company’s stock had a trading volume of 28,708 shares, compared to its average volume of 43,851. Mesa Laboratories has a fifty-two week low of $82.86 and a fifty-two week high of $145.46. The company has a quick ratio of 1.86, a current ratio of 0.37 and a debt-to-equity ratio of 0.58. The firm’s fifty day moving average price is $107.94 and its 200-day moving average price is $106.75. The firm has a market capitalization of $761.91 million, a price-to-earnings ratio of -2.99 and a beta of 0.86.

Mesa Laboratories (NASDAQ:MLAB) last released its quarterly earnings results on Wednesday, June 5th. The medical instruments supplier reported $2.25 earnings per share for the quarter. Mesa Laboratories had a positive return on equity of 10.10% and a negative net margin of 117.61%. The firm had revenue of $58.90 million during the quarter. On average, equities research analysts expect that Mesa Laboratories will post 6.91 EPS for the current year.

Institutional Investors Weigh In On Mesa Laboratories

Several large investors have recently made changes to their positions in MLAB. Boone Capital Management LLC acquired a new stake in shares of Mesa Laboratories in the 4th quarter valued at approximately $6,712,000. Motley Fool Asset Management LLC raised its stake in Mesa Laboratories by 643.8% in the 1st quarter. Motley Fool Asset Management LLC now owns 64,776 shares of the medical instruments supplier’s stock valued at $7,108,000 after acquiring an additional 56,067 shares during the period. Meros Investment Management LP bought a new stake in Mesa Laboratories in the 2nd quarter valued at $2,456,000. Raymond James & Associates raised its stake in Mesa Laboratories by 58.4% in the 1st quarter. Raymond James & Associates now owns 74,456 shares of the medical instruments supplier’s stock valued at $8,170,000 after acquiring an additional 27,437 shares during the period. Finally, Keeley Teton Advisors LLC bought a new stake in Mesa Laboratories in the 1st quarter valued at $2,606,000. Institutional investors and hedge funds own 90.60% of the company’s stock.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions.